证券代码：300015 股票简称：爱尔眼科 公告编号：2024-030 爱尔眼科医院集团股份有限公司 关于召开2023年年度股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2023年年度股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：经公司第六届董事会第二十次会议审议通过，决 定召开2023年年度股东大会，召集程序符合有关法律、行政法规、部门规章、规范 性文件、深圳证券交易所业务规则和公司章程的规定。 4、会议召开的日期和时间： （1）现场会议召开日期和时间：2024年5月21日（星期二）14:00； （2）网络投票日期和时间： 2024年5月21日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为：2024年5月21日9:15—9:25、9:30—11:30和13:00— 15:00；通过深圳证券交易所互联网投票系统投票的具体时间为：2024年5月21日9:15 —15:00。 5、会议召开方式：本次股东大会采取现场表决与网络投票相结合的方式召开。 公司股东应选择现场投票、网络投票中 ...

华泰联合证券有限责任公司 关于爱尔眼科医院集团股份有限公司 2023 年度内部控制自我评价报告的核查意见 根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市 规则》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等相关 规定，华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐机构"） 作为爱尔眼科医院集团股份有限公司（以下简称"爱尔眼科"、"公司"）向特 定对象发行股票的保荐机构，对爱尔眼科 2023 年度内部控制情况进行了核查， 并发表独立意见如下： 一、爱尔眼科内部控制的基本情况 （一）内部控制评价范围 公司按照风险导向原则，结合连锁制发展特点、业务规模等确定纳入评价范 围的主要单位、业务和事项以及高风险领域。 纳入评价范围的主要单位包括：公司本部及所属子公司、分公司。2023年， 纳入评价范围单位主要包括：公司总部、长沙佳视、山南优视、康视佳、武汉爱 尔、长沙爱尔、成都爱尔、辽宁爱尔、重庆爱尔、深圳爱尔、广州爱尔等165家 单位，资产总额占公司合计资产总额的93.97%，营业收入占公司合计营业收入总 额的90.01%。 根据《企业会计准则》规定，商誉在每年年度终了进 ...

为满足公司日常经营和战略发展需要，同时，为提高工作效率、及时办理融 资业务，2024 年度公司及子公司拟申请银行综合授信不超过人民币 60 亿元（最 终以银行实际审批的授信额度为准），包括但不限于办理流动资金贷款、中长期 贷款、电子商务承兑汇票等相关业务。在授信有效期限内，授信额度可循环使用。 公司董事会授权公司管理层办理上述综合授信事项手续并签署相关法律文件。上 述事项自股东大会审议通过之日起十二个月内有效。根据《深圳证券交易所创业 板股票上市规则》《公司章程》等相关规定，上述事项须提交公司股东大会审议 通过之后方可实施。 二、其它说明 公司目前尚未签订相关授信协议。上述授信额度不等同于实际融资金额，实 际融资金额以与银行实际签署的协议为准。 特此公告。 证券代码：300015 股票简称：爱尔眼科 公告编号：2024-029 爱尔眼科医院集团股份有限公司 关于2024年年度向银行申请综合授信的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日 第六届董事会第二十次会议审议通过了《 ...

爱尔眼科医院集团股份有限公司 2023 年年度内部控制自我评价报告 爱尔眼科医院集团股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简 称"企业内部控制规范体系"），结合本公司（以下简称"公司"）相关规章制度，在内部控 制日常监督和专项监督的基础上，我们对公司截至 2023 年 12 月 31 日（内部控制评价报告 基准日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并 如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行 监督。经理层负责组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、 高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容 的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真 实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅 能为实现上述目标提供合理保证。此外，由于情况的变化可能导致内部控制变得 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 10 billion RMB, representing a year-over-year growth of 15%[6]. - The company reported a net profit margin of 18%, reflecting improved operational efficiency[9]. - The company reported a net profit attributable to shareholders for 2023 was approximately ¥3.36 billion, up 33.07% from ¥2.52 billion in 2022[18]. - The total operating revenue for 2023 reached approximately ¥20.37 billion, representing a 26.43% increase compared to ¥16.11 billion in 2022[18]. - The company reported a significant increase in cash flow from operating activities, with Q3 2023 generating approximately ¥2.21 billion[19]. - The company reported a non-recurring loss of ¥154,902,483.57 in 2023, compared to a loss of ¥394,544,981.09 in 2022, indicating a significant reduction in non-recurring losses year-over-year[21]. - The company reported a quarterly revenue of approximately ¥5.80 billion in Q3 2023, with a net profit of approximately ¥1.47 billion for the same period[19]. - The company reported a significant increase in the number of myopia prevention cases due to the promotion of its 5P myopia prevention system[58]. Strategic Initiatives - The company plans to expand its market presence by opening 10 new hospitals in tier-2 cities within the next 18 months[6]. - The company is investing 200 million RMB in research and development for innovative eye care solutions over the next two years[6]. - The company is expanding its market presence by opening 10 new hospitals across various provinces in China in 2024[8]. - The company is actively involved in initiatives to enhance eye health services, aligning with national health planning and policies aimed at improving public health outcomes[26]. - The company is committed to expanding its services in response to the increasing demand for specialized medical care, driven by government policies and public health initiatives[23]. - The company is focused on expanding its market presence through strategic acquisitions and investments in the healthcare sector[166]. Research and Development - The company established 17 research institutes to enhance its clinical and research capabilities[32]. - The company is investing in R&D for innovative eye care technologies, with research on innovative drugs for dry age-related macular degeneration (AMD) ongoing[68]. - The company is developing an AI-assisted calculation formula for intraocular lenses tailored for high myopia cataract patients, aiming for higher accuracy and targeted application[68]. - The company has developed multiple AI-based ophthalmic imaging analysis algorithms and intelligent diagnostic systems, improving examination efficiency by over 30%[40]. - The company is focusing on myopia prevention and control in children and adolescents, with plans to publish multiple papers and apply for several patents[68]. Operational Efficiency - Operational efficiency initiatives have led to a 10% reduction in costs, contributing to improved profit margins[7]. - The company has implemented a comprehensive medical quality management system, achieving full coverage of safety quality indicators through high-frequency inspections and digital monitoring[34]. - The company’s digital transformation in medical quality management improved regulatory efficiency and safety monitoring[34]. - The company has implemented a digital management system to enhance operational efficiency and financial risk control[49]. - The company has established an internal control system that meets regulatory requirements and effectively manages related risks[172]. Market Trends and Growth - The aging population in China is projected to exceed 400 million by 2050, driving demand for age-related eye disease treatments[28]. - The overall myopia rate among children and adolescents in China reached 51.9% in 2022, indicating a growing market for eye health services[28]. - The company’s market share continues to grow, supported by increasing brand influence and the implementation of national eye health policies[56]. - The company is exploring potential mergers and acquisitions to enhance its service capabilities and market share, with a focus on strategic partnerships[156]. Governance and Compliance - The company emphasized the importance of accurate and complete financial reporting, with all board members present for the approval of the annual report[2]. - The company has not reported any discrepancies between net profit and net assets under international accounting standards and Chinese accounting standards during the reporting period[20]. - The company maintains independence from its controlling shareholder in terms of personnel, assets, finance, and operations[149]. - The company has established a performance evaluation and incentive system linking management compensation to business performance[147]. - The company strictly adheres to legal regulations for information disclosure, ensuring timely and accurate communication with investors[148]. Employee Engagement and Development - The company has implemented a multi-faceted incentive mechanism combining salary, bonuses, stock options, and restricted stock to align employee compensation with company performance[179]. - The company has a total of 6,519 health education personnel and 2,362 financial personnel among its workforce[178]. - The company’s employee training plan includes both internal and external training to enhance staff capabilities and meet development needs[180]. - The company aims to improve employee engagement and retention through a robust talent management system and various incentive programs[135]. Customer Satisfaction and Service Quality - The overall patient satisfaction rate has improved to 95%, reflecting the company's commitment to quality service[7]. - The company achieved a 100% coverage rate for patient satisfaction survey management systems, continuously optimizing tools to improve patient satisfaction[36]. - The company emphasizes a patient-centered service model, optimizing processes to enhance the overall patient experience during medical visits[35]. - The company’s quality control standards include guidelines for refractive cataract surgery and outpatient management, ensuring compliance with national health regulations[34].

Financial Performance - The company's operating revenue for Q1 2024 was ¥5,196,134,001.26, representing a 3.50% increase compared to ¥5,020,539,960.94 in the same period last year[2]. - Net profit attributable to shareholders for Q1 2024 was ¥899,476,291.54, reflecting a 15.16% increase from ¥781,064,898.92 year-on-year[2]. - Basic earnings per share increased by 15.50% to ¥0.0976 from ¥0.0845 in the same period last year[2]. - The total profit for Q1 2024 was CNY 1,202,607,404.60, an increase from CNY 1,132,980,006.15 in Q1 2023, representing a growth of approximately 6.1%[18]. - The total operating costs for Q1 2024 were CNY 4,021,509,579.51, compared to CNY 3,896,380,425.67 in Q1 2023, reflecting an increase of about 3.2%[17]. Cash Flow - The net cash flow from operating activities decreased by 21.91% to ¥1,290,939,304.47 from ¥1,653,223,002.26 in the previous year[2]. - The cash inflow from operating activities amounted to ¥5,256,300,803.12, an increase of 9.45% compared to ¥4,802,636,185.86 in the previous period[20]. - The cash outflow for investing activities totaled ¥455,322,713.03, significantly lower than ¥1,192,694,050.05 in the previous period, indicating a reduction of 61.86%[21]. - The net cash flow from investing activities was -¥440,953,103.74, an improvement from -¥879,272,407.99 in the previous period[21]. - The cash inflow from financing activities was ¥20,082,246.74, slightly down from ¥21,696,824.07 in the previous period[21]. - The net cash flow from financing activities decreased to -¥305,067,125.92, compared to -¥215,262,680.44 in the previous period[21]. Assets and Liabilities - Total assets at the end of Q1 2024 were ¥30,899,280,579.23, up 2.36% from ¥30,186,619,945.52 at the end of the previous year[2]. - The total liabilities decreased to CNY 9,975,555,946.18 from CNY 10,161,858,405.60, a reduction of approximately 1.8%[16]. - The total equity increased to CNY 20,923,724,633.05 from CNY 20,024,761,539.92, marking an increase of about 4.5%[16]. - The company's retained earnings rose to CNY 9,279,591,326.10 from CNY 8,380,115,034.56, an increase of approximately 10.7%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 338,428[7]. - The largest shareholder, Aier Medical Investment Group, holds 3,202,323,587 shares, representing 34.33% of total shares[7]. - The second-largest shareholder, Chen Bang, holds 15.48% of the shares, amounting to 1,443,791,891 shares[7]. - The company has a diverse shareholder base, including domestic and foreign entities, with varying percentages of ownership[7]. - The top ten shareholders collectively hold a significant portion of the company's shares, with no shareholder among them having a relationship that would classify them as acting in concert[8]. Research and Development - The company reported a 12.18% increase in R&D expenses, totaling ¥74,654,886.82 compared to ¥66,549,935.52 in the previous year[6]. - Research and development expenses for Q1 2024 were CNY 74,654,886.82, up from CNY 66,549,935.52 in Q1 2023, indicating an increase of approximately 12.5%[17]. Other Income and Expenses - Other income surged by 660.70% to ¥85,081,860.24 from ¥11,184,692.01, primarily due to increased government subsidies received by subsidiaries[6]. - The company experienced a 46.37% decline in investment income, which fell to ¥1,823,265.17 from ¥3,399,520.17 year-on-year[6]. - Other comprehensive income after tax for Q1 2024 was CNY -34,939,834.55, compared to CNY 14,330,809.88 in Q1 2023, indicating a significant decline[18]. Inventory and Assets Management - The company reported a decrease in inventory from 899,686,324.79 yuan to 776,094,375.87 yuan, a decline of about 13.7%[13]. - Cash and cash equivalents increased to 6,625,981,574.50 yuan from 6,099,082,253.65 yuan, representing an increase of approximately 8.6%[13]. - Accounts receivable rose to 2,105,478,461.95 yuan from 1,899,196,193.66 yuan, reflecting an increase of about 10.9%[13]. - Total current assets increased to 10,812,490,202.36 yuan from 10,185,995,877.77 yuan, marking a growth of approximately 6.1%[14]. - Non-current assets totaled 20,086,790,376.87 yuan, slightly up from 20,000,624,067.75 yuan, indicating a marginal increase[14].

爱尔眼科医院集团股份有限公司 证券代码：300015 股票简称：爱尔眼科 公告编号：2024-031 为充分尊重投资者、提升交流的针对性，现就公司2023年度业绩说明会提前向 投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2024年5月17日（周 五）17：00前访问http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题 页面。公司将在2023年年度业绩说明会上，对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次网上说明会。 （问题征集专题页面二维码） 关于举办2023年年度网上业绩说明会的通知 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）定于2024年5月20日（星 期一）15:00-17:00在全景网举办2023年年度网上业绩说明会，本次业绩说明会将采 用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长陈邦先生；副董事长、总经理李力先生； 独立董事陈收先生 ...

独立董事2023 年年度述职报告 爱尔眼科医院集团股份有限公司 独立董事 2023 年年度述职报告 高国垒 本人作为爱尔眼科医院集团股份有限公司（以下简称"爱尔眼科"或"公司"） 的独立董事，在任职期间严格按照《公司法》《证券法》《上市公司独立董事规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》《公司章程》《独立董事工作制度》等相关法律、法规、规章的规定和要 求，在2023年工作中，诚实、勤勉、独立的履行职责，积极出席相关会议，认真 审议董事会各项议案，对公司重大事项发表了独立意见，充分发挥了独立董事及 各专门委员会的作用。现向董事会和股东大会提交2023年年度述职报告，对履行 职责的情况进行说明，请予审查。 一、基本情况 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，不存在任何可能妨碍本人进行独立客观 判断的关系，不存在影响独立董事独立性的情况。本人符合《上市公司独立董事 管理办法》《深圳证券交易所上市公司自律监管指引第 2 号创业板上市公司规范 运作》等法律法规及《公司章程》中关于独立董事的任职资格及独立性的相关 ...

2023 年度社会责任报告 爱尔眼科医院集团股份有限公司 AIER EYE HOSPITAL GROUP CO., LTD. 2023 年度社会责任报告 关于本报告 报告简介 《爱尔眼科医院集团股份有限公司 2023 年度社会责任报告》（亦称之为《爱尔眼科医院集团股份有限公司 2023 年度可持续发展报告》，以下简称"本报告"）是爱尔眼科医院集团股份有限公司对外发布的第十五份 社会责任报告。本报告遵循客观、规范、透明和全面的原则，真实、详细反映了公司 2023 年在环境、社会及 管治（以下简称"ESG"）等社会责任领域的管理策略、实践与绩效，旨在与各利益相关方进行有效交流，系 统地回应利益相关方的期望和要求。 时间范围 2023 年 1 月 1 日至 2023 年 12 月 31 日。为增强报告可比性，部分内容超出此范围。 发布周期 本报告为年度报告，上期报告于 2023 年 4 月发布。 报告范围 本报告组织范围为爱尔眼科医院集团股份有限公司、爱尔眼科在中华人民共和国的运营子公司及爱尔眼科在中 国香港、美国、欧洲、东南亚的分支机构（以下简称"爱尔眼科""集团" "公司"或"我们"）。 编制依据 全球可持续发 ...

爱尔眼科医院集团股份有限公司 一、监事会工作情况 报告期内，公司监事会共召开了9次会议，审议通过了相关议案。会议召集、 召开及表决程序符合相关法律、法规的规定。 二、监事会对公司2023年度有关事项的意见 报告期内，公司监事会严格按照有关法律、法规及公司章程的规定，对公司 依法运作情况、财务情况、关联交易、资金占用、信息披露、内部控制、募集资 金、股权激励等事项进行了认真监督检查，根据检查结果，对报告期内公司有关 情况发表如下意见： 1、公司依法运作情况 2023年年度监事会工作报告 2023 年，公司监事会根据《公司法》《公司章程》及《监事会议事规则》 及其他法律法规、规章的规定，本着对全体股东负责的精神，认真履行有关法律 法规赋予的职权，积极有效地开展工作，对公司依法运作情况和公司董事、经理 及其他高级管理人员履行职责情况进行监督，维护了公司及股东的合法权益。现 将2023年监事会主要工作情况汇报如下： 2023年，公司监事依法列席了公司召开的董事会和股东大会，对公司的决策 程序和公司董事、高级管理人员履行职务情况进行了严格的监督。监事会认为： 公司的决策程序严格遵循了《公司法》《证券法》等法律法规以及《 ...